387 related articles for article (PubMed ID: 24583420)
1. Graves' ophthalmopathy: epidemiology and natural history.
Hiromatsu Y; Eguchi H; Tani J; Kasaoka M; Teshima Y
Intern Med; 2014; 53(5):353-60. PubMed ID: 24583420
[TBL] [Abstract][Full Text] [Related]
2. Childhood Graves' ophthalmopathy: results of a European questionnaire study.
Krassas GE; Segni M; Wiersinga WM
Eur J Endocrinol; 2005 Oct; 153(4):515-21. PubMed ID: 16189172
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology, Natural History, Risk Factors, and Prevention of Graves' Orbitopathy.
Bartalena L; Piantanida E; Gallo D; Lai A; Tanda ML
Front Endocrinol (Lausanne); 2020; 11():615993. PubMed ID: 33329408
[TBL] [Abstract][Full Text] [Related]
4. Graves' ophthalmopathy and 131I therapy.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Mazzi B; Rocchi R; Barbesino G; Pinchera A
Q J Nucl Med; 1999 Dec; 43(4):307-12. PubMed ID: 10731781
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology and prevention of Graves' ophthalmopathy.
Wiersinga WM; Bartalena L
Thyroid; 2002 Oct; 12(10):855-60. PubMed ID: 12487767
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for development or deterioration of Graves' ophthalmopathy.
Stan MN; Bahn RS
Thyroid; 2010 Jul; 20(7):777-83. PubMed ID: 20578901
[TBL] [Abstract][Full Text] [Related]
7. Pediatric aspects in Graves' orbitopathy.
Gogakos AI; Boboridis K; Krassas GE
Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():234-44. PubMed ID: 20467370
[TBL] [Abstract][Full Text] [Related]
8. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment.
Stan MN; Durski JM; Brito JP; Bhagra S; Thapa P; Bahn RS
Thyroid; 2013 May; 23(5):620-5. PubMed ID: 23205939
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and natural history of Graves' orbitopathy in the XXI century.
Piantanida E; Tanda ML; Lai A; Sassi L; Bartalena L
J Endocrinol Invest; 2013 Jun; 36(6):444-9. PubMed ID: 23587873
[TBL] [Abstract][Full Text] [Related]
10. Pathophysiology of Graves' ophthalmopathy.
Stiebel-Kalish H; Robenshtok E; Gaton DD
Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():178-81. PubMed ID: 20467359
[TBL] [Abstract][Full Text] [Related]
11. Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies.
Chen DY; Schneider PF; Zhang XS; Luo XY; He ZM; Chen TH
Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):1-6. PubMed ID: 24203649
[TBL] [Abstract][Full Text] [Related]
12. Prevention of Graves' ophthalmopathy.
Bartalena L
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):371-9. PubMed ID: 22632372
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of Graves' orbitopathy (GO) and relationship with thyroid disease.
Lazarus JH
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):273-9. PubMed ID: 22632364
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of Graves' ophthalmopathy in patients with Graves' disease presenting to a referral centre in north India.
Reddy SV; Jain A; Yadav SB; Sharma K; Bhatia E
Indian J Med Res; 2014 Jan; 139(1):99-104. PubMed ID: 24604044
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center.
Tanda ML; Piantanida E; Liparulo L; Veronesi G; Lai A; Sassi L; Pariani N; Gallo D; Azzolini C; Ferrario M; Bartalena L
J Clin Endocrinol Metab; 2013 Apr; 98(4):1443-9. PubMed ID: 23408569
[TBL] [Abstract][Full Text] [Related]
16. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.
Woo YJ; Jang SY; Lim TH; Yoon JS
Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504
[TBL] [Abstract][Full Text] [Related]
17. [Graves' orbitopathy].
Eckstein A; Esser J
Klin Monbl Augenheilkd; 2011 May; 228(5):432-8. PubMed ID: 21534176
[TBL] [Abstract][Full Text] [Related]
18. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial.
Brammen L; Riss P; Lukas J; Gessl A; Dunkler D; Li S; Leisser A; Rezar-Dreindl S; Eibenberger K; Selberherr A; Scheuba C; Papp A
Trials; 2018 Sep; 19(1):495. PubMed ID: 30219088
[TBL] [Abstract][Full Text] [Related]
19. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
[TBL] [Abstract][Full Text] [Related]
20. Limited genetic susceptibility to severe Graves' ophthalmopathy: no role for CTLA-4 but evidence for an environmental etiology.
Villanueva R; Inzerillo AM; Tomer Y; Barbesino G; Meltzer M; Concepcion ES; Greenberg DA; MacLaren N; Sun ZS; Zhang DM; Tucci S; Davies TF
Thyroid; 2000 Sep; 10(9):791-8. PubMed ID: 11041456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
